Mission
THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.
Public Charity
QUANTUM LEAP HEALTHCARE COLLABORATIVE
QUANTUM LEAP HEALTHCARE COLLABORATIVE is a nonprofit organization categorized as Public Charity based in SAN FRANCISCO, CA. Its most recent IRS filing (2024) reports revenue of $45.5M, expenses of $62.6M, total assets of $40.2M. Imperigo tracks 25 reported grant relationships connected to this organization totaling approximately $1.5M.
EIN: 204284925
SAN FRANCISCO, CA
Human Service Organizations
NTEE: P20
Latest filing: 2024
Total Revenue$45.5M
Total Expenses$62.6M
Total Assets$40.2M
Grant Records25
Funding Total$1.5M
Filing Years2020–2024
Where $100 goes at Quantum Leap Healthcare Collaborative
How Quantum Leap Healthcare Collaborative divides every $100 it spends, from its own Form 990 filings, averaged across 8 years.
$92
Programs
the work itself
$7
Management
running the organization
$1
Fundraising
raising the next dollar
Inside the $92 for programs
$52
Ispy 2.2 - I-spy 2.2 uses a 'sequential multiple assignment randomized trial' (smart) design - that is both smart and adaptive
$36
Other programs include breast cancer trials (bct) match, COVID-19 trials, I-spy 2.0, endocrince optimization project (eop) trials, and one source ai
$4
Dcis
Plus 1 more program. Cost per person served and the full program breakdown are on the full profile.
Source: Form 990 filings with the IRS, latest fiscal year 2024. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.
Sample Grants Received
PROGRAM SUPPORT
$10,000
CANCER PREVENTION AND TREATMENT
$200,000
UNRESTRICTED GENERAL SUPPORT
$20,000
HUMAN SERVICES
$12,000
For grant recipient's exempt purposes
$11,250
Showing up to 5 of 25 total records — full history available with membership.
Officers & Directors
CHIEF DATA OFFICER
Adam Asare
DIRECTOR OF I-SPY COVID TRIAL
Ami Okada
DIRECTOR
Anna Barker Phd
VP BIOMARKER & INNOVATION
Annuska Glas
CHAIRMAN
Dave Mandelkern Ms
DIRECTOR
Gregory C Simon
Officer compensation and complete director data available with membership.
Top Grant Purposes
Financial Trends
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $45.5M | $62.6M | $40.2M |
| 2023 | $45.1M | $47.8M | $58.2M |
| 2022 | $47.3M | $47.2M | $60.9M |
| 2021 | $56.1M | $43.8M | $64.4M |
| 2020 | $41.0M | $23.6M | $46.7M |
Between 2020 and 2024, reported annual revenue grew from $41.0M to $45.5M (+11%), with total assets most recently reported at $40.2M.
Interactive year-over-year charts and full filing details available with membership.